No Data
China Grants Hutchmed Breakthrough Designation for Non-Small Cell Lung Cancer Drug
Reported Earlier, HUTCHMED's ORPATHYS and TAGRISSO Combo Gains Therapy Designation in China for Advanced Lung Cancer
Hutchmed (China) (00013.HK) announced that the combination therapy of Orpathys and Tagrisso has been included as a breakthrough therapy in China for the treatment of specific lung cancer patients with disease progression after EGFR inhibitor treatment.
On December 12, Glonghui reported that Hutchmed (China) (00013.HK) announced today that the Drug Evaluation Center of the National Medical Products Administration of China ("National Drug Administration") has included Orpathys (savolitinib) and Tagrisso (osimertinib) in the list of breakthrough therapeutic drugs, for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have progressed after receiving epidermal growth factor receptor ("EGFR") inhibitors, accompanied by MET amplification. Orpathys is
Express News | HUTCHMED Announces Breakthrough Therapy Designation in China for Orpathys® and Tagrisso® Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy
China Central Economic Work Conference: A Key Indicator for Future Market Trends
Tonight, Chinese concepts soared! The nasdaq Golden Dragon index surged by 10%, while fangdd network doubled directly.
Some analysis indicates that the Political Bureau meeting first mentioned stabilizing the stock and real estate markets, and the US stock market quickly rallied on china assets. The 3x Long FTSE china etf surged over 26%, the 2x Long china internet plus-related stocks rose over 22%, the 2x Long FTSE china 50 ETF increased over 17%, and the 2x Long 300etf gained nearly 15%.
